Bipolar Disorder Market Analysis By Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), By Mechanism of Action, By Region, And Segment Forecasts, 2014 - 2025

  • ID: 4452068
  • Report
  • 95 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan Plc.
  • AstraZeneca
  • Eli Lily
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • MORE
The global bipolar disorder market is anticipated to reach USD 4.9 billion by 2025, growing at a CAGR of 2.10%. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient’s mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation’s Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient’s mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Further Key Findings From the Study Suggest:
  • The antipsychotic segment is expected to dominate the market owing to increasing prevalence of psychosis, and physical illness resulting in depression.
  • The serotonin norepinephrine reuptake inhibitor segment is anticipated to dominate the market in the forecast period. The growth of this segment is due to these drugs being primarily used to treat major depression and bipolar disorder, and having better safety profile and tolerability.
  • North America is expected to dominate global bipolar disorder market. This can be attributed to the high stress levels, insufficient sleep, and trend of substance abuse amongst the population.
  • Some of the major players in this space include GlaxoSmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Co. Ltd, and AstraZeneca.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan Plc.
  • AstraZeneca
  • Eli Lily
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • MORE
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Bipolar disorder Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of bipolar disorder
3.1.1.2 Increasing government support
3.1.1.3 Technological advancements
3.1.2 Market restraint analysis
3.1.2.1 Side effects associated with bipolar drugs
3.1.2.2 Misdiagnosis of bipolar disorder
3.2 Penetration & Growth Prospect Mapping
3.3 SWOT Analysis, By Factor (political & legal, economic, and technological)
3.3.1 Market SWOT Analysis, By Factor (political & legal, economic, and technological)
3.4 Industry Analysis - Porter’s
3.4.1 Porter’s Five Forces analysis

Chapter 4 Bipolar disorder Drug Class Estimates & Trend Analysis
4.1 Bipolar disorder Market: Drug Class Movement Analysis
4.2 Mood stabilizer
4.2.1 Mood stabilizer market estimates & forecasts, 2014 - 2025 (USD Million)
4.3 Anticonvulsants
4.3.1 Anticonvulsant market estimates & forecasts, 2014 - 2025 (USD Million)
4.4 Antipsychotic drugs
4.4.1 Antipsychotic drugs market estimates & forecasts, 2014 - 2025 (USD Million)
4.5 Antidepressant drugs
4.5.1 Antidepressant drugs market estimates & forecasts, 2014 - 2025 (USD Million)
4.6 Antianxiety drugs
4.6.1 Antianxiety drugs market estimates & forecasts, 2014 - 2025 (USD Million)

Chapter 5 Bipolar disorder Mechanism of Action Estimates & Trend Analysis
5.1 Bipolar disorder Market: Mechanism of Action Movement Analysis
5.2 Selective serotonin reuptake inhibitor
5.2.1 Selective serotonin reuptake inhibitor market estimates & forecasts, 2014 - 2025 (USD Million)
5.3 Serotonin norepinephrine reuptake inhibitor
5.3.1 Serotonin norepinephrine reuptake inhibitor market estimates & forecasts, 2014 - 2025 (USD Million)
5.4 Tricyclic antidepressants
5.4.1 Tricyclic antidepressants market estimates & forecasts, 2014 - 2025 (USD Million)
5.5 Monoamine oxidase inhibitor
5.5.1 Monoamine oxidase inhibitor market estimates & forecasts, 2014 - 2025 (USD Million)
5.6 Benzodiazepines
5.6.1 Benzodiazepines market estimates & forecasts, 2014 - 2025 (USD Million)
5.7 Benzodiazepines
5.7.1 Beta blockers market estimates & forecasts, 2014 - 2025 (USD Million)
5.8 Others
5.8.1 Others market estimates & forecasts, 2014 - 2025 (USD Million)

Chapter 6 Bipolar disorder Regional Estimates & Trend Analysis, by Drug Class, and Mechanism of Action.
6.1 Bipolar disorder Market Share By Region, 2016 & 2025
6.2 North America
6.2.1 North America bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.3.4 France
6.3.4.1 France bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa bipolar disorder market estimates & forecasts, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Company Profiles
7.2.1 GlaxoSmithKline
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Pfizer Inc.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Janssen Pharmaceuticals
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Eli Lily
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Allergan Plc.
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Norvartis
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 AbbVie Inc.
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Otsuka Holdings Co.Ltd
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 AstraZeneca
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives

List of Tables

Table 1 North America bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 2 North America bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025 (USD Million)
Table 3 U.S. bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 4 U.S. bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 5 Canada bipolar disorder market estimates and forecast by drug class, 2014 - 2025 (USD Million)
Table 6 Canada bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 7 Europe bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 8 Europe bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025
Table 9 U.K bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 10 U.K bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025 (USD Million)
Table 11 Germany bipolar disorder vitamin market estimates and forecast by drug class, 2014 - 2025 (USD Million)
Table 12 Germany bipolar disorder antioxidants market estimates and forecast by mechanism of action, 2014 - 2025
Table 13 Asia Pacific bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 14 Asia Pacific bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025 (USD Million)
Table 15 China bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 16 China bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 17 Japan bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 18 Japan bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 19 Latin America other bipolar disorder market estimates and forecast by drug classs, 2014 - 2025 (USD Million)
Table 20 Latin America bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025
Table 21 Brazil bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 22 Brazil bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 23 Mexico bipolar disorder market estimates and forecast by drug class, 2014 - 2025 (USD Million)
Table 24 Mexico bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025
Table 25 Middle East Asia bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 26 Middle East Asia bipolar disorder market estimates and forecast by mechanism of action, 2014 - 2025 (USD Million)
Table 27 South Africa bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 28 South Africa bipolar disorder market estimates and forecast by mechanism of action (USD Million)
Table 29 Saudi Arabia bipolar disorder market estimates and forecast by drug class, 2014 - 2025
Table 30 Saudi Arabia bipolar disorder market estimates and forecast by mechanism of action (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016 (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and social)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Bipolar disorder market drug class outlook key takeaways
FIG. 16 Bipolar disorder market: drug class movement analysis
FIG. 17 Global mood stabilizer market, 2014 - 2025 (USD Million)
FIG. 18 Global anticonvulsant market, 2014 - 2025 (USD Million)
FIG. 19 Global antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 20 Global antidepressant drug market, 2014 - 2025 (USD Million)
FIG. 21 Global antianxiety drugs market, 2014 - 2025 (USD Million)
FIG. 22 Bipolar disorder market mechanism of action outlook key takeaways
FIG. 23 Bipolar disorder market: mechanism of action movement analysis
FIG. 24 Global selective serotonin reuptake inhibitor market, 2014 - 2025 (USD Million)
FIG. 25 Global serotonin norepinephrine reuptake inhibitor market, 2014 - 2025 (USD Million)
FIG. 26 Global tricyclic antidepressants market, 2014 - 2025 (USD Million)
FIG. 27 Global monoamine oxidase inhibitors market, 2014 - 2025 (USD Million)
FIG. 28 Global benzodiazephines market, 2014 - 2025 (USD Million)
FIG. 29 Global beta blockers equipment market, 2014 - 2025 (USD Million)
FIG. 30 Global others equipment market, 2014 - 2025 (USD Million)
FIG. 31 Regional market place: Key takeaways
FIG. 32 Regional outlook, 2016 & 2025
FIG. 33 North America bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 34 U.S. bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 35 Canada bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 36 Europe bipolar disorder market, 2013 - 2024 (USD Million)
FIG. 37 UK bipolar disorder market, 2013 - 2024 (USD Million)
FIG. 38 Germany bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 39 Asia Pacific bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 40 Japan bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 41 China bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 42 Latin America bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 43 Brazil bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 44 Mexico bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 45 MEA bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 46 South Africa bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 47 Saudi Arabia bipolar disorder market, 2014 - 2025 (USD Million)
FIG. 48 Strategy framework
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • Eli Lily
  • Allergan Plc.
  • Norvartis
  • AbbVie Inc.
  • Otsuka Holdings Co.Ltd
  • AstraZeneca
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll